You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

5 items

Cytogenetic analysis (karyotyping) for all new diagnoses of MDS, MPN, or MDS/MPN in line with established criteria.

Funded Biomarker Disease Site: Hematology
Biomarker: TBC
Testing Method:Cytogenetics (Karyotyping)
Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Trillium Health Partners, University Health Network

Evaluation of genomic biomarkers in cases of MDS, MPN, or MDS/MPN for diagnostic sub-classification, prognosis or therapeutic guidance.

Funded Biomarker Disease Site: Hematology
Biomarker: TBC
Testing Method:Panel
Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, University Health Network

FISH analysis in cases of MDS, MPN, MDS/MPN where karyotyping is insufficient or criteria for additional testing is met.

Funded Biomarker Disease Site: Hematology
Biomarker: TBC
Testing Method:Fluoroscence In Situ Hybridization (FISH)
Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Trillium Health Partners, University Health Network

Repeat FLT3 testing of adult patients with relapsed or refractory acute myeloid leukemia being considered for therapy with Gilteritinib.

Funded Biomarker Disease Site: Hematology
Biomarker: FLT3
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, The Ottawa Hospital, University Health Network

Testing on previously untreated CLL/SLL patients once therapy is being considered.

Funded Biomarker Disease Site: Hematology
Biomarker: Chromosome 17p Deletion or TP53 Mutation or Unmutated Immunoglobulin Heavy Chain Variable Region (IgHV)
Testing Method:N/A
Testing Site: Health Sciences North, University Health Network